Zacks Investment Research on MSN
MRK stock gains after CHMP backs Keytruda combo for bladder cancer
Shares of Merck MRK rose nearly 6% on Friday after the company announced that the EMA’s Committee for Medicinal Products for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results